Table of Contents Author Guidelines Submit a Manuscript
Journal of Obesity
Volume 2011, Article ID 898013, 6 pages
Research Article

Switching to Aripiprazole as a Strategy for Weight Reduction: A Meta-Analysis in Patients Suffering from Schizophrenia

Abarbanel Mental Health Center and Geha Mental Health Center Affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Bat-Yam 59100, Israel

Received 17 April 2010; Revised 15 July 2010; Accepted 28 July 2010

Academic Editor: S. B. Heymsfield

Copyright © 2011 Yoram Barak and Dov Aizenberg. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [15 citations]

The following is the list of published articles that have cited the current article.

  • Zulfat Miftahutdinov, and Elena Tutubalina, “End-to-end deep framework for disease named entity recognition using social media data,” 2017 IEEE 30th Neumann Colloquium (NC), pp. 000047–000052, . View at Publisher · View at Google Scholar
  • M. Bragau, G. Piriu, C. Cosma, A. Rotaru, M. D. Mosescu, and A. F. Barjoveanu, “Weight loss in a patient with schizophrenia treated with aripiprazole - case report,” European Neuropsychopharmacology, vol. 22, pp. S331–S331, 2012. View at Publisher · View at Google Scholar
  • Jean-Pierre Schuster, Delphine Raucher-Chéné, Cédric Lemogne, Frédéric Rouillon, Isabelle Gasquet, Denis Leguay, Fabien Gierski, Jean-Michel Azorin, and Frédéric Limosin, “Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia,” Journal of Clinical Psychopharmacology, vol. 32, no. 5, pp. 672–677, 2012. View at Publisher · View at Google Scholar
  • Yuejin Chen, William V. Bobo, Kara Watts, Karuna Jayathilake, Tinlai Tang, and Herbert Y. Meltzer, “Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study,” Journal of Psychopharmacology, vol. 26, no. 9, pp. 1201–1210, 2012. View at Publisher · View at Google Scholar
  • Nilufar Mossaheb, and Rainer M. Kaufmann, “Role of aripiprazole in treatment-resistant schizophrenia,” Neuropsychiatric Disease and Treatment, vol. 8, pp. 235–244, 2012. View at Publisher · View at Google Scholar
  • Ursula Werneke, David Taylor, and Thomas A. B. Sanders, “Behavioral Interventions for Antipsychotic Induced Appetite Changes,” Current Psychiatry Reports, vol. 15, no. 3, 2013. View at Publisher · View at Google Scholar
  • Diane H. Fredrikson, Heidi N. Boyda, Lurdes Tse, Zachary Whitney, Mark A. Pattison, Fred J. Ott, Laura Hansen, and Alasdair M. Barr, “Improving Metabolic and Cardiovascular Health at an Early Psychosis Intervention Program in Vancouver, Canada,” Frontiers in Psychiatry, vol. 5, 2014. View at Publisher · View at Google Scholar
  • Richard Musil, Michael Obermeier, Paul Russ, and Michael Hamerle, “Weight gain and antipsychotics: a drug safety review,” Expert Opinion on Drug Safety, pp. 1–24, 2014. View at Publisher · View at Google Scholar
  • Andrea Murru, Diego Hidalgo, Miquel Bernardo, Julio Bobes, Jerónimo Saiz-Ruiz, Cecilio Álamo, and Eduard Vieta, “Antipsychotic switching in schizoaffective disorder: A systematic review,” The World Journal of Biological Psychiatry, pp. 1–19, 2015. View at Publisher · View at Google Scholar
  • Glen L. Xiong, and Zhongshu Yang, “Managing obesity in patients with mental illness: A literature review and implication for clinical practice,” Current Psychiatry Reviews, vol. 11, no. 4, pp. 290–297, 2015. View at Publisher · View at Google Scholar
  • Jonathan M. Meyer, Yongcai Mao, Andrei Pikalov, Josephine Cucchiaro, and Antony Loebel, “Weight change during long-term treatment with lurasidone: Pooled analysis of studies in patients with schizophrenia,” International Clinical Psychopharmacology, vol. 30, no. 6, pp. 342–350, 2015. View at Publisher · View at Google Scholar
  • Su Ling Young, Mark Taylor, and Stephen M. Lawrie, “"first do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects,” Journal of Psychopharmacology, vol. 29, no. 4, pp. 353–362, 2015. View at Publisher · View at Google Scholar
  • Keiko Naono-Nagatomo, Hisao Naono, Hiroshi Abe, Ryuichiro Takeda, Hideki Funahashi, Daisuke Uchimura, and Yasushi Ishida, “Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: a case series,” Asian Journal of Psychiatry, 2016. View at Publisher · View at Google Scholar
  • Suhashini Ratnatunga, Chathurie Suraweera, Varuni A de Silva, Madhubhashinee Dayabandara, Raveen Hanwella, and Sudarshi Seneviratne, “Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence,” Neuropsychiatric Disease and Treatment, vol. 13, pp. 2231–2241, 2017. View at Publisher · View at Google Scholar
  • Aleksandra Gorostowicz, and Marcin Siwek, “The role of aripiprazole in the treatment of schizophrenia and mood disorders,” Psychiatria i Psychologia Kliniczna, vol. 18, no. 3, pp. 296–305, 2018. View at Publisher · View at Google Scholar